These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 29036837)

  • 1. Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.
    Carroll CB; Wyse RKH
    J Parkinsons Dis; 2017; 7(4):545-568. PubMed ID: 29036837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
    Carroll CB; Webb D; Stevens KN; Vickery J; Eyre V; Ball S; Wyse R; Webber M; Foggo A; Zajicek J; Whone A; Creanor S
    BMJ Open; 2019 Oct; 9(10):e029740. PubMed ID: 31594876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
    Kumar A; Sharma N; Gupta A; Kalonia H; Mishra J
    Brain Res; 2012 Aug; 1471():13-22. PubMed ID: 22789904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.
    Wolozin B; Wang SW; Li NC; Lee A; Lee TA; Kazis LE
    BMC Med; 2007 Jul; 5():20. PubMed ID: 17640385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin reverses the downregulation of M1/4 receptor binding in 6-hydroxydopamine-induced parkinsonian rats: the association with improvements in long-term memory.
    Wang Q; Wei X; Gao H; Li J; Liao J; Liu X; Qin B; Yu Y; Deng C; Tang B; Huang XF
    Neuroscience; 2014 May; 267():57-66. PubMed ID: 24613723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with
    Pierzchlińska A; Droździk M; Białecka M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.
    Stevens KN; Creanor S; Jeffery A; Whone A; Zajicek J; Foggo A; Jones B; Chapman R; Cocking L; Wilks J; Webb D; Carroll C;
    JAMA Neurol; 2022 Dec; 79(12):1232-1241. PubMed ID: 36315128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
    Tison F; Nègre-Pagès L; Meissner WG; Dupouy S; Li Q; Thiolat ML; Thiollier T; Galitzky M; Ory-Magne F; Milhet A; Marquine L; Spampinato U; Rascol O; Bezard E
    Parkinsonism Relat Disord; 2013 Apr; 19(4):416-21. PubMed ID: 23283428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects of statins in Parkinson disease.
    Roy A; Pahan K
    Neuroscientist; 2011 Jun; 17(3):244-55. PubMed ID: 21252380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts.
    Swallow DM; Lawton MA; Grosset KA; Malek N; Klein J; Baig F; Ruffmann C; Bajaj NP; Barker RA; Ben-Shlomo Y; Burn DJ; Foltynie T; Morris HR; Williams N; Wood NW; Hu MT; Grosset DG
    J Neurol Neurosurg Psychiatry; 2016 Nov; 87(11):1183-1190. PubMed ID: 27671901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current insights into pathogenesis of Parkinson's disease: Approach to mevalonate pathway and protective role of statins.
    Saeedi Saravi SS; Saeedi Saravi SS; Khoshbin K; Dehpour AR
    Biomed Pharmacother; 2017 Jun; 90():724-730. PubMed ID: 28419968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
    Lancellotti P; Pierard LA; Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the role of statins in Parkinson's disease risk reduction and disease modification: A comprehensive meta-analysis of 4 million participants' data.
    Mady A; Nabil Y; Daoud A; Alnajjar AZ; Alsalloum T; Marwan M; Abdelmeseh M; Elsayed M; Krayim A; Alaa M; Masoud M; Bushara N; Faisal R; Ahmed H; Saad M; Belabaci Z; Barrett MJ; Berman B; Negida A
    CNS Neurosci Ther; 2024 Aug; 30(8):e14888. PubMed ID: 39097909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration.
    Saeedi Saravi SS; Saeedi Saravi SS; Arefidoust A; Dehpour AR
    Metab Brain Dis; 2017 Aug; 32(4):949-965. PubMed ID: 28578514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size.
    Yamakuchi M; Greer JJ; Cameron SJ; Matsushita K; Morrell CN; Talbot-Fox K; Baldwin WM; Lefer DJ; Lowenstein CJ
    Circ Res; 2005 Jun; 96(11):1185-92. PubMed ID: 15905463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
    Päivä H; Thelen KM; Van Coster R; Smet J; De Paepe B; Mattila KM; Laakso J; Lehtimäki T; von Bergmann K; Lütjohann D; Laaksonen R
    Clin Pharmacol Ther; 2005 Jul; 78(1):60-8. PubMed ID: 16003294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study.
    Nguyen TTH; Fournier A; Courtois É; Artaud F; Escolano S; Tubert-Bitter P; Boutron-Ruault MC; Degaey I; Roze E; Canonico M; Ahmed I; Thiébaut ACM; Elbaz A
    Mov Disord; 2023 May; 38(5):854-865. PubMed ID: 36788159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.